Anti-acne agents attenuate FGFR2 signal transduction in acne.
Increased fibroblast growth factor receptor-2 (FGFR2) signaling has been proposed to be involved in acne pathogenesis and explains acne lesions in Apert syndrome and unilateral acneiform nevus associated with gain-of-function point mutations of FGFR2. If, indeed, increased FGFR2 signaling plays a major pathogenic role in follicular hyperkeratinization and sebaceous gland hypertrophy in acne, effective anti-acne drugs may attenuate increased FGFR2 signaling. The purpose of this article is to elucidate the hypothesis that known anti-acne agents may operate by downregulation of increased FGFR2 signaling. Anti-androgens suppress FGF-ligand expression, benzoyl peroxide induces FGFR2 downregulation by lysosomal receptor degradation, azelaic acid inhibits mitochondrial ATP formation required for receptor tyrosine kinase phosphorylation, tetracyclines inhibit the expression, and activity of FGFR2b downstream matrix metalloproteinases, and retinoids attenuate the FGFR2 pathway at several regulatory levels of the signal transduction cascade critical for cell cycle control, cell proliferation, differentiation, and lipogenesis. Erythromycin, a P-450 inhibitor, may interfere with FGFR2 signaling by its inhibitory effect on retinoid catabolism. The gain-of-function mutations of FGFR2 in Apert syndrome and unilateral acneiform nevus, and the proposed synergistic inhibitory interactions of anti-acne agents at various levels of the FGFR2-signaling cascade underline the role of FGFR2 signaling in the pathogenesis of acne.
Melnik
Bodo C
BC
Department of Dermatology, Environmental Medicine and Health Theory, University of Osnabrück, Osnabrück, Germany. Melnik@t-online.de
Schmitz
Gerd
G
Zouboulis
Christos C
CC
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000209:etiology; D000726:Androgen Antagonists / Q000494:pharmacology; D001585:Benzoyl Peroxide / Q000494:pharmacology; D003998:Dicarboxylic Acids / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D006801:Humans; D053582:Interleukin-1alpha / Q000096:biosynthesis; D015474:Isotretinoin / Q000494:pharmacology; D017382:Reactive Oxygen Species; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D013754:Tetracyclines / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology; D000521:alpha-MSH / Q000494:pharmacology
D000726:Androgen Antagonists; D001585:Benzoyl Peroxide; D003998:Dicarboxylic Acids; D004917:Erythromycin; D053582:Interleukin-1alpha; D015474:Isotretinoin; D017382:Reactive Oxygen Species; D018719:Erb-b2 Receptor Tyrosine Kinases; D013754:Tetracyclines; D014212:Tretinoin; D000521:alpha-MSH; C508053:ERBB2 protein, human; C010038:azelaic acid